Ruti Aga's Six Years: The Ban Came From a Piece of Paper, Not the Track

In March, Ruti Aga won a half marathon in China. Which city, which race, in what time — none of the three appears in the published report. What exists is a sample, a laboratory report, and a prescription with no registered physician's signature behind it, only the name of a family member. Forty-seven years of standing at the rail of a track taught me this: the first results sheet is never just paper, it is a doorway. Open that door and what you see is an empty first row — the winner of a race nobody named has been erased.

One erased name means one loss on the track and one blank in the ledger. The 2026 Tokyo Marathon title stands untouched by this decision. She has three World Marathon Major runner-up finishes. Put those three facts together and you get a second-tier elite marathoner — somewhere in the global top fifteen to twenty-five of her generation, consistent, bankable, a regular podium guest, but never the athlete the event was built around. One Major win and three Major runner-up finishes point to a particular income structure, which I will come to.

The level of those Majors matters. Her peak window, 2026 to 2026, falls inside the first generation of carbon-plate road shoes. Times fell across both marathon fields in that era, and to place a runner honestly you need course profile, pacing format (women-only or mixed) and shoe generation. None of those three appears in the published report, so a shoe-era-adjusted reading of her best marks is not possible. What can be said is that she is not record tier; she is a high-elite athlete sitting roughly eight to nine minutes behind the record tier.

She is thirty-two. The marathon's extended peak usually runs from twenty-seven to thirty-three, with outliers past thirty-five. She was at the far edge of the peak, exactly where the body and the earnings both need more medical support to stay durable. This is where the terminology needs clearing up, because sports journalism uses these words carelessly.

Methylprednisolone is a glucocorticoid — a class of drug used to reduce inflammation. Knee pain, patellofemoral loading, the accumulated inflammation of a long season: this is the class a clinic reaches for first in all of those cases. Under the WADA framework, glucocorticoids are prohibited only in-competition, and only by injection, oral or rectal route. Out of competition, under a documented physician's care, with a Therapeutic Use Exemption where needed, the drug is legitimate. The treatment she described is not, by itself, illegal. The problem is not the treatment.

Her explanation was a knee injury. For a marathoner that explanation is credible, and that is the most uncomfortable part of this case — the story could have been true. The rule was broken on timing, not on the drug. Glucocorticoids are prohibited in-competition, so an injection documented a few days before the race survives scrutiny, while a detectable presence on race day does not. A legitimate treatment, on the wrong schedule, becomes an adverse analytical finding.

What happened next is the centre of this story. The bulk of the sanction came not from doping but from paper. The prescription submitted was written by a family member with no medical registration, who claimed to have used an old prescription pad from a former workplace; the clinic flatly denied it. At that point the case stopped being an adverse analytical finding and became tampering and process abuse, and the arithmetic of the sentence changed.

The six-year calculation is simple and should be understood first. A base anti-doping violation normally carries up to four years. Here a tampering charge was added. The total is six years, running from 10 September, preceded by a provisional suspension. A ban that begins at thirty-two ends at thirty-eight.

On paper that number looks harmless. In practice it is the end of a career. Returning at thirty-eight is not impossible — the marathon has exceptional longevity. But six years outside the competitive system means six years outside the agent-managed calendar, six years outside the altitude camps, six years off the invitation lists of the Majors. Training does not fill that gap.

The annulment question also needs separating, because people conflate two things. Only the result at the competition where the sample was collected is disqualified — the March half marathon title, its prize money and ranking points. The 2026 Tokyo title is untouched. In ledger terms that matters: one result erased, one retained.

Now the layer least discussed: where the test happened. A March half marathon in China, unnamed, is not the elite circuit. It is a label-level road race, appearance-fee driven, without international broadcast pressure, and its testing footprint is set by the local anti-doping organisation and targeted Athletics Integrity Unit work rather than by the race's commercial profile. That combination creates a specific risk zone for a mid-tier elite: high fee, low surveillance.

How the testing architecture works is worth one paragraph, because readers see the words daily without knowing the tiers. At international level there are three. In-competition testing — before or after a race, which is the direct cause of a result annulment. Out-of-competition testing — at home, at camp, at a training centre, which requires whereabouts filings. And the biological passport — a long blood series that catches changes no single test can. This case is the first kind. She was caught by the test that offers the least room to plan.

Here is my own ledger discipline. In 2026 at the National Stadium in Dhaka, during the SAF Games, I held my first results sheet: a carbon copy, hand-timed, with no electronic timing anywhere in the stadium. Since that week I have held one rule — what is not written down I do not trust to memory. This report is missing four things: the race name, the winning time, the sample type (urine or blood) and the year of the decision. Four gaps make the athlete's position impossible to fix, and that is a failure of journalism before it is anything else.

Look at the income structure and the scale of the blow becomes clear. One Major win and three Major runner-up finishes mean a small global sponsorship market; the core earnings come from appearance fees and podium bonuses. Both dry up the moment the ban lands. The loss is close to total, not marginal.

The deeper structural problem is not the treatment but the channel. A registered team physician would have known which drug is prohibited in-competition, how to file an exemption, where the paperwork goes. That role was filled by a family member with no registration, whose paper trail a clinic itself disowned. In the Ethiopian high-altitude marathon pipeline — the Addis Ababa, Sululta, Asella belt — a personal coach and an agent-run calendar are standard, while medical support often rests on informal relationships. That is my inference, not something the report states; but an environment in which a family member writes a prescription supports it.

The central insight of this case: the sentence is not for the doping, it is for the handling of the doping. And that handling grew out of neglect, not conspiracy.

First, the strongest version of the World Athletics and AIU position. Their task is hard. If prescriptions can be forged and survive, the Therapeutic Use Exemption system becomes meaningless; every genuinely ill athlete falls under suspicion; if documentation does not protect you, nobody keeps documentation. On that reasoning a six-year message is preventive, and not unreasonable.

Two discomforts remain. First, balance. The underlying violation — an in-competition glucocorticoid presence — could have been resolved inside two years; paper tripled it. The system punishes the athlete's worst instinct, and that instinct is born of fear: two years for the truth, six for trying to hide it. A regime that makes surrender the most expensive option quietly rewards forgery.

Second, the surveillance asymmetry. The least-tested athlete received the longest ban, and that is not coincidence. The label-race economy runs on appearance fees, and testing density is thinnest exactly there. Where surveillance is low, detection is the rare event; and when detection comes, the reaction is at its most chaotic. A regulator serious about this risk should watch the second tier of the road calendar, not the elite track circuit.

A third question has no answer in the report: who was that family member, and what did they gain? The ban carries the athlete's name; the prescription carries someone else's liability. In entourage-run systems that imbalance is ordinary — the risk belongs to the athlete, control of the decisions belongs to someone else.

The question ahead is not whether Ruti Aga comes back; that answer is largely written. The question is where the next case comes from. The answer is the same place: a label race like March's, an appearance fee, a half marathon win, and a clinic where the prescription is written by a relative. The 2027 road calendar will show whether the regulator educated that zone or merely punished it.

One more thing. A stopwatch can start a career, but a ledger decides what it meant. Ruti Aga's ledger now holds two rows — a Tokyo 2026, intact; and a March race, unnamed, untimed, erased. The question is which row ours will keep.